CompletedPhase 1NCT02710500
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
Studying Qualitative or quantitative defects of dysferlin
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarepta Therapeutics, Inc.
- Principal Investigator
- Jerry R Mendell, MDDirector, Center for Gene Therapy
- Intervention
- rAAVrh74.MHCK7.DYSF.DV(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2019
Study locations (1)
- Nationwide Children's Hosptial, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02710500 on ClinicalTrials.gov